Differences in the product characteristics and clinical use of granulocytes for transfusion: The BEST Collaborative study.

IF 2.5 3区 医学 Q2 HEMATOLOGY
Transfusion Pub Date : 2025-05-15 DOI:10.1111/trf.18263
Lorna Cain, Charles Lafrance, Suzy Morton, Catherine Latour, Mélissa Girard, Pierre Tiberghien, Virginie de la Taille, Suvro Sankha Datta, Mrigender Singh Virk, Jennifer Andrews, Vered Yahalom, Ana María Pugliese, Romina Alba, Richard Charlewood, Susy Kirwan, Ana Paula Hitomi Yokoyama, Jose Mauro Kutner, Eva Alonso Nogues, Nuria Martinez I Llonch, James Daly, David O Irving, Torsten J Schulze, Elise Huisman, Kaatje Le Poole, Hans Vrielink, Nabiha H Saifee, Monica B Pagano, Simon Stanworth
{"title":"Differences in the product characteristics and clinical use of granulocytes for transfusion: The BEST Collaborative study.","authors":"Lorna Cain, Charles Lafrance, Suzy Morton, Catherine Latour, Mélissa Girard, Pierre Tiberghien, Virginie de la Taille, Suvro Sankha Datta, Mrigender Singh Virk, Jennifer Andrews, Vered Yahalom, Ana María Pugliese, Romina Alba, Richard Charlewood, Susy Kirwan, Ana Paula Hitomi Yokoyama, Jose Mauro Kutner, Eva Alonso Nogues, Nuria Martinez I Llonch, James Daly, David O Irving, Torsten J Schulze, Elise Huisman, Kaatje Le Poole, Hans Vrielink, Nabiha H Saifee, Monica B Pagano, Simon Stanworth","doi":"10.1111/trf.18263","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Whether granulocytes for transfusion are beneficial remains uncertain, although some evidence suggests that efficacy may be dose-related. Granulocytes are mostly produced by apheresis procedure, but other means of production are increasingly used.</p><p><strong>Methods: </strong>Centers that produce and/or use granulocytes were recruited through the BEST Collaborative and completed a detailed survey of granulocyte manufacture, specifications, clinical use, operational considerations, and data collection initiatives.</p><p><strong>Results: </strong>Fifteen national, regional, and local producers and/or users of granulocytes were included. Granulocytes were produced from apheresis procedure (n = 10), pooled buffy coats (n = 2), single buffy coats (n = 4) or pooling of residual leukocyte units from whole blood processing (n = 1). The mean adult dose of granulocytes reported was 1.6 to 3.7 × 10<sup>10</sup> for apheresis, and 1.8 to 2.2 × 10<sup>10</sup> for pooled buffy coat granulocytes. For apheresis procedure donations, donor stimulation included steroids and/or granulocyte colony-stimulating factor. Centers providing whole blood-derived granulocytes reported shorter times from request to delivery than those using apheresis procedure products. Indications and product selection criteria were similar. The most frequently reported challenges with granulocytes were donor availability for apheresis procedure (n = 7), short shelf life (n = 5) and lack of evidence of efficacy (n = 5). The cost of one unit of apheresis procedure granulocytes ranged from 568 to 7500 PPP-USD, and for one pooled buffy coat unit was from 2208 to 2822 PPP-USD.</p><p><strong>Conclusions: </strong>We have highlighted differences in granulocyte production that are relevant for the design and interpretation of much needed international clinical studies.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/trf.18263","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Whether granulocytes for transfusion are beneficial remains uncertain, although some evidence suggests that efficacy may be dose-related. Granulocytes are mostly produced by apheresis procedure, but other means of production are increasingly used.

Methods: Centers that produce and/or use granulocytes were recruited through the BEST Collaborative and completed a detailed survey of granulocyte manufacture, specifications, clinical use, operational considerations, and data collection initiatives.

Results: Fifteen national, regional, and local producers and/or users of granulocytes were included. Granulocytes were produced from apheresis procedure (n = 10), pooled buffy coats (n = 2), single buffy coats (n = 4) or pooling of residual leukocyte units from whole blood processing (n = 1). The mean adult dose of granulocytes reported was 1.6 to 3.7 × 1010 for apheresis, and 1.8 to 2.2 × 1010 for pooled buffy coat granulocytes. For apheresis procedure donations, donor stimulation included steroids and/or granulocyte colony-stimulating factor. Centers providing whole blood-derived granulocytes reported shorter times from request to delivery than those using apheresis procedure products. Indications and product selection criteria were similar. The most frequently reported challenges with granulocytes were donor availability for apheresis procedure (n = 7), short shelf life (n = 5) and lack of evidence of efficacy (n = 5). The cost of one unit of apheresis procedure granulocytes ranged from 568 to 7500 PPP-USD, and for one pooled buffy coat unit was from 2208 to 2822 PPP-USD.

Conclusions: We have highlighted differences in granulocyte production that are relevant for the design and interpretation of much needed international clinical studies.

输血中粒细胞产品特性和临床应用的差异:BEST合作研究。
背景:输注粒细胞是否有益仍不确定,尽管一些证据表明疗效可能与剂量有关。粒细胞主要是通过单采过程产生的,但其他生产手段也越来越多地使用。方法:通过BEST协作组招募生产和/或使用粒细胞的中心,并完成对粒细胞制造、规格、临床使用、操作考虑和数据收集计划的详细调查。结果:包括15个国家、地区和地方的粒细胞生产者和/或使用者。粒细胞来源于单采过程(n = 10)、合并的黄皮层(n = 2)、单一的黄皮层(n = 4)或全血处理过程中残留的白细胞单位(n = 1)。据报道,单胞粒细胞的平均成年剂量为1.6 ~ 3.7 × 1010,聚集的白皮毛粒细胞的平均成年剂量为1.8 ~ 2.2 × 1010。对于单采供体,供体刺激包括类固醇和/或粒细胞集落刺激因子。提供全血源性粒细胞的中心报告从请求到交付的时间比使用单采程序产品的中心要短。适应症和产品选择标准相似。最常见的粒细胞挑战报告是供体可采性(n = 7),保质期短(n = 5)和缺乏有效性证据(n = 5)。单个单采过程中粒细胞的成本在568 - 7500 PPP-USD之间,而一个集合的白大衣单位的成本在2208 - 2822 PPP-USD之间。结论:我们强调了与急需的国际临床研究的设计和解释相关的粒细胞产生的差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Transfusion
Transfusion 医学-血液学
CiteScore
4.70
自引率
20.70%
发文量
426
审稿时长
1 months
期刊介绍: TRANSFUSION is the foremost publication in the world for new information regarding transfusion medicine. Written by and for members of AABB and other health-care workers, TRANSFUSION reports on the latest technical advances, discusses opposing viewpoints regarding controversial issues, and presents key conference proceedings. In addition to blood banking and transfusion medicine topics, TRANSFUSION presents submissions concerning patient blood management, tissue transplantation and hematopoietic, cellular, and gene therapies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信